small cell carcinoma, sarcomatoid urothelial carcinoma, micropapillary carcinoma, plasmacytoid carcinoma, adenocarcinoma, and urachal carcinoma. The role of neoadjuvant and adjuvant chemotherapy ...
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback